Literature DB >> 24995948

Predicting diffusive transport of cationic liposomes in 3-dimensional tumor spheroids.

Michael G Wientjes1, Bertrand Z Yeung2, Ze Lu1, M Guillaume Wientjes1, Jessie L S Au3.   

Abstract

Nanotechnology is widely used in cancer research. Models that predict nanoparticle transport and delivery in tumors (including subcellular compartments) would be useful tools. This study tested the hypothesis that diffusive transport of cationic liposomes in 3-dimensional (3D) systems can be predicted based on liposome-cell biointerface parameters (binding, uptake, retention) and liposome diffusivity. Liposomes comprising different amounts of cationic and fusogenic lipids (10-30mol% DOTAP or 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine, 1-20mol% DOPE or 1,2-dioleoyl-3-trimethylammonium-propane, +25 to +44mV zeta potential) were studied. We (a) measured liposome-cell biointerface parameters in monolayer cultures, and (b) calculated effective diffusivity based on liposome size and spheroid composition. The resulting parameters were used to simulate the liposome concentration-depth profiles in 3D spheroids. The simulated results agreed with the experimental results for liposomes comprising 10-30mol% DOTAP and ≤10mol% DOPE, but not for liposomes with higher DOPE content. For the latter, model modifications to account for time-dependent extracellular concentration decrease and liposome size increase did not improve the predictions. The difference among low- and high-DOPE liposomes suggests concentration-dependent DOPE properties in 3D systems that were not captured in monolayers. Taken together, our earlier and present studies indicate the diffusive transport of neutral, anionic and cationic nanoparticles (polystyrene beads and liposomes, 20-135nm diameter, -49 to +44mV) in 3D spheroids, with the exception of liposomes comprising >10mol% DOPE, can be predicted based on the nanoparticle-cell biointerface and nanoparticle diffusivity. Applying the model to low-DOPE liposomes showed that changes in surface charge affected the liposome localization in intratumoral subcompartments within spheroids.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  3-Dimensional tumors; Cationic liposomes; Diffusive transport; Fusogenic lipid; Nanoparticle; Spatiokinetics

Mesh:

Substances:

Year:  2014        PMID: 24995948      PMCID: PMC4169740          DOI: 10.1016/j.jconrel.2014.06.050

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  17 in total

Review 1.  Delivery of siRNA therapeutics: barriers and carriers.

Authors:  Jie Wang; Ze Lu; M Guillaume Wientjes; Jessie L-S Au
Journal:  AAPS J       Date:  2010-06-11       Impact factor: 4.009

2.  On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids.

Authors:  I M Hafez; N Maurer; P R Cullis
Journal:  Gene Ther       Date:  2001-08       Impact factor: 5.250

3.  Clinical aspects of drug delivery to tumors.

Authors:  Jessie L-S Au; Seong H Jang; M Guill Wientjes
Journal:  J Control Release       Date:  2002-01-17       Impact factor: 9.776

4.  Binding and interstitial penetration of liposomes within avascular tumor spheroids.

Authors:  Kostas Kostarelos; Dimitris Emfietzoglou; Alexandros Papakostas; Wei-Hong Yang; Ase Ballangrud; George Sgouros
Journal:  Int J Cancer       Date:  2004-11-20       Impact factor: 7.396

5.  Fusion of cationic liposomes with mammalian cells occurs after endocytosis.

Authors:  I Wrobel; D Collins
Journal:  Biochim Biophys Acta       Date:  1995-05-04

6.  The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer.

Authors:  H Farhood; N Serbina; L Huang
Journal:  Biochim Biophys Acta       Date:  1995-05-04

Review 7.  Drug delivery and transport to solid tumors.

Authors:  Seong Hoon Jang; M Guillaume Wientjes; Dan Lu; Jessie L S Au
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

8.  Fusogenic activity of cationic lipids and lipid shape distribution.

Authors:  Caroline Lonez; Marc F Lensink; Emilie Kleiren; Jean-Marie Vanderwinden; Jean-Marie Ruysschaert; Michel Vandenbranden
Journal:  Cell Mol Life Sci       Date:  2009-11-19       Impact factor: 9.261

9.  Tumor priming enhances delivery and efficacy of nanomedicines.

Authors:  Dan Lu; M Guillaume Wientjes; Ze Lu; Jessie L-S Au
Journal:  J Pharmacol Exp Ther       Date:  2007-04-09       Impact factor: 4.030

Review 10.  Nanoparticle therapeutics: an emerging treatment modality for cancer.

Authors:  Mark E Davis; Zhuo Georgia Chen; Dong M Shin
Journal:  Nat Rev Drug Discov       Date:  2008-09       Impact factor: 84.694

View more
  5 in total

Review 1.  Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities.

Authors:  Jessie L-S Au; Bertrand Z Yeung; Michael G Wientjes; Ze Lu; M Guillaume Wientjes
Journal:  Adv Drug Deliv Rev       Date:  2015-12-11       Impact factor: 15.470

Review 2.  Transport of drugs from blood vessels to tumour tissue.

Authors:  Mark W Dewhirst; Timothy W Secomb
Journal:  Nat Rev Cancer       Date:  2017-11-10       Impact factor: 60.716

Review 3.  Target Site Delivery and Residence of Nanomedicines: Application of Quantitative Systems Pharmacology.

Authors:  Jessie L-S Au; Roberto A Abbiati; M Guillaume Wientjes; Ze Lu
Journal:  Pharmacol Rev       Date:  2019-04       Impact factor: 25.468

4.  Effect of shape, size, and aspect ratio on nanoparticle penetration and distribution inside solid tissues using 3D spheroid models.

Authors:  Rachit Agarwal; Patrick Jurney; Mansi Raythatha; Vikramjit Singh; Sidlgata V Sreenivasan; Li Shi; Krishnendu Roy
Journal:  Adv Healthc Mater       Date:  2015-09-16       Impact factor: 11.092

Review 5.  Drug delivery to solid tumors: the predictive value of the multicellular tumor spheroid model for nanomedicine screening.

Authors:  Marie Millard; Ilya Yakavets; Vladimir Zorin; Aigul Kulmukhamedova; Sophie Marchal; Lina Bezdetnaya
Journal:  Int J Nanomedicine       Date:  2017-10-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.